Long-Acting Semaglutide Microspheres: A New Formulation That Could Mean Monthly Dosing

Adding hydroxyethyl starch to semaglutide-loaded PLGA microspheres achieved 94% encapsulation, 83% controlled release over 44 days, and nearly three weeks of glycemic control in animal studies.

Zeng, Han et al.·International journal of pharmaceutics·2024·Preliminary Evidencein vitro
RPEP-09627In vitroPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=not applicable
Participants
In vitro PLGA microsphere formulations containing semaglutide

What This Study Found

HES-containing PLGA microspheres achieved 94.38% semaglutide encapsulation, 83.23% controlled release over 44 days, prevented 30.65% drug loss versus HES-free microspheres, and provided ~3 weeks of glycemic control in vivo.

Key Numbers

HES addition to the W1 phase showed significant enhancement of semaglutide stability compared to formulations without the starch protectant.

How They Did This

Formulation study using W1/O/W2 double emulsion method to create PLGA microspheres. Tested hydroxyethyl starch addition at various concentrations. Characterized encapsulation efficiency, in vitro release kinetics, semaglutide structural integrity, and in vivo glycemic control.

Why This Research Matters

Weekly semaglutide injections are a barrier to patient adherence. A monthly injectable microsphere formulation would significantly reduce injection burden, potentially improving outcomes for millions of diabetes and obesity patients.

The Bigger Picture

As GLP-1 drugs become the most important class of metabolic medications, extending their dosing intervals is a top pharmaceutical priority. This microsphere approach could apply not just to semaglutide but to other peptide drugs that currently require frequent injections, representing a platform technology for long-acting peptide delivery.

What This Study Doesn't Tell Us

Primarily in vitro formulation work with limited in vivo data. Human pharmacokinetics, bioavailability, and injection-site tolerability are unknown. Scale-up manufacturing challenges for microspheres are not addressed. The ~3 weeks of glycemic control observed in animals may not translate directly to humans.

Questions This Raises

  • ?Can this microsphere formulation achieve once-monthly dosing in human clinical trials?
  • ?How does the injection-site experience compare to current weekly semaglutide injections?
  • ?Could this PLGA-HES platform be applied to other peptide drugs like tirzepatide or liraglutide?

Trust & Context

Key Stat:
44-day release Semaglutide microspheres with HES achieved controlled drug release over 44 days, compared to the current weekly injection schedule
Evidence Grade:
Preliminary evidence: well-characterized formulation study with encouraging in vitro results and limited in vivo data. No human clinical trial data yet.
Study Age:
Published in 2024. Reflects active research into next-generation semaglutide delivery systems.
Original Title:
Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.
Published In:
International journal of pharmaceutics, 654, 123991 (2024)
Database ID:
RPEP-09627

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Could semaglutide become a monthly injection?

This microsphere technology achieved controlled semaglutide release over 44 days in lab tests and ~3 weeks of blood sugar control in animals. If clinical trials succeed, monthly or even less frequent semaglutide injections could become reality.

What are PLGA microspheres?

PLGA is a biodegradable polymer used in many approved medical products. Microspheres are tiny drug-loaded beads injected under the skin that slowly dissolve and release medication over weeks to months, eliminating the need for frequent injections.

Read More on RethinkPeptides

Cite This Study

RPEP-09627·https://rethinkpeptides.com/research/RPEP-09627

APA

Zeng, Han; Song, Jiaxin; Li, Yiyao; Guo, Chen; Zhang, Yu; Yin, Tian; He, Haibing; Gou, Jingxin; Tang, Xing. (2024). Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.. International journal of pharmaceutics, 654, 123991. https://doi.org/10.1016/j.ijpharm.2024.123991

MLA

Zeng, Han, et al. "Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.." International journal of pharmaceutics, 2024. https://doi.org/10.1016/j.ijpharm.2024.123991

RethinkPeptides

RethinkPeptides Research Database. "Effect of hydroxyethyl starch on drug stability and release ..." RPEP-09627. Retrieved from https://rethinkpeptides.com/research/zeng-2024-effect-of-hydroxyethyl-starch

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.